Literature DB >> 29557531

Beta-blocker therapy is associated with a lower incidence of syncope due to fast ventricular tachycardias among implantable cardioverter-defibrillator patients with left ventricular dysfunction: results from a multicenter study.

Javier Jiménez-Candil1, Ignasi Anguera2, Olga Durán3, Jesús Hernández3, Javier Fernández-Portales4, José Luis Moríñigo3, Ana Martín3, Paolo Dallaglio2, Loreto Bravo3, Andrea di Marco2, Pedro Luis Sánchez3.   

Abstract

INTRODUCTION: Among implantable cardioverter-defibrillator (ICD) patients, a substantial proportion of syncopes are due to fast ventricular tachycardias (FVTs). In the experimental models of ventricular tachycardias, the arterial vasoconstriction plays an important role in recovering the arterial pressure. Since beta-blockers increase vascular resistance, we hypothesized that beta-blockers could reduce the occurrence of syncope due to FVTs. Our objective was to determine the relationship between the beta-blocker therapy and the incidence of syncope in FVT (cycle length [CL] 250-320 ms) occurring in ICD patients. Slow VTs were excluded because of the lack of symptoms and VF episodes because of the small number. METHODS AND
RESULTS: In this multicenter study, 226 patients (LVEF 31 ± 10%) with single-chamber ICDs were followed. FVT programming was standardized, including antitachycardia pacing (ATP) as initial therapy. Symptoms were correlated with ICD-stored episode data of FVTs. The beta-blocker therapy was determined at each FVT presentation. We analyzed 289 FVTs (CL 291 ± 21 ms; 77% under beta-blockers; median of the duration:8 s) occurring consecutively in 52 ICD patients. The frequency of FVT-related syncope was 22 (7.6%). Beta-blockers were associated with a lower heart rate preceding FVT (85 ± 22 vs. 94 ± 23 bpm; p = 0.009), a higher ATP effectiveness (86 vs. 57%; p < 0.001), a lower duration of episodes (8 [2] vs. 10 [14] s; p < 0.001), and a lower incidence of FVT-related syncope (4.5 vs. 18%; p < 0.001). By logistic regression, a FVT > 8 s (OR = 21; p = 0.003) and the beta-blocker therapy (OR = 0.3; p = 0.012) were found as independent predictors of syncope.
CONCLUSION: Among ICD patients with left ventricular dysfunction, beta-blockers are associated with a lower incidence of FVT-related syncope.

Entities:  

Keywords:  Beta-blocker treatment; Implantable cardiac defibrillator; Syncope; Ventricular tachycardia

Mesh:

Substances:

Year:  2018        PMID: 29557531     DOI: 10.1007/s10840-018-0344-0

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  24 in total

1.  Morphology of far-field electrograms and antitachycardia pacing effectiveness among fast ventricular tachycardias occurring in ICD patients: a multicenter study.

Authors:  Javier Jiménez-Candil; Ignasi Anguera; Claudio Ledesma; Javier Fernández-Portales; José Luis Moríñigo; Paolo Dallaglio; Ana Martín; Teresa Cano; Jesús Hernández; Xavier Sabaté; Cándido Martín-Luengo
Journal:  J Cardiovasc Electrophysiol       Date:  2013-09-09

2.  Syncope in high-risk cardiomyopathy patients with implantable defibrillators: frequency, risk factors, mechanisms, and association with mortality: results from the multicenter automatic defibrillator implantation trial-reduce inappropriate therapy (MADIT-RIT) study.

Authors:  Martin H Ruwald; Ken Okumura; Takeshi Kimura; Kazutaka Aonuma; Morio Shoda; Valentina Kutyifa; Anne-Christine H Ruwald; Scott McNitt; Wojciech Zareba; Arthur J Moss
Journal:  Circulation       Date:  2013-11-07       Impact factor: 29.690

3.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

4.  Influence of beta-blocker therapy on antitachycardia pacing effectiveness for monomorphic ventricular tachycardias occurring in implantable cardioverter-defibrillator patients: a dose-dependent effect.

Authors:  Javier Jiménez-Candil; Jesús Hernández; Ana Martín; María Ruiz-Olgado; Jesús Herrero; Claudio Ledesma; José Moríñigo; Cándido Martín-Luengo
Journal:  Europace       Date:  2010-06-04       Impact factor: 5.214

5.  Syncope following cardioverter defibrillator implantation in patients with spontaneous syncopal monomorphic ventricular tachycardia.

Authors:  Mauricio Abello; José L Merino; Rafael Peinado; Mariana Gnoatto; Miguel A Arias; Mar Gonzalez-Vasserot; José A Sobrino
Journal:  Eur Heart J       Date:  2005-09-23       Impact factor: 29.983

6.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

7.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.

Authors: 
Journal:  N Engl J Med       Date:  1997-11-27       Impact factor: 91.245

8.  Discrimination of ventricular tachycardia from sinus tachycardia and atrial fibrillation in a tiered-therapy cardioverter-defibrillator.

Authors:  C D Swerdlow; P S Chen; R M Kass; J R Allard; C T Peter
Journal:  J Am Coll Cardiol       Date:  1994-05       Impact factor: 24.094

9.  Different effects of beta-1-adrenergic blocking agents with ISA or without ISA on peripheral blood flow.

Authors:  R Karnik; A Valentin; J Slany
Journal:  Angiology       Date:  1987-04       Impact factor: 3.619

10.  Value of ventricular electrogram recordings in the diagnosis of arrhythmias precipitating electrical device shock therapy.

Authors:  B G Hook; F E Marchlinski
Journal:  J Am Coll Cardiol       Date:  1991-03-15       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.